SUMOylation is a post-translational modification consisting of the covalent addition of SUMO peptides on a target protein, which can affect various processes such as protein stability, interactions or subcellular localizations. This modification finetunes protein function involved in the cellular response to stress, differentiation and tissue development.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have identified benzoxazinone derivatives acting as mineralocorticoid receptor (MR) antagonists reported to be useful for the treatment of diabetic nephropathy.
Scientists in Edinburgh are planning a clinical trial of licensed drugs in the prevention of chronic kidney disease (CKD) following acute kidney injury (AKI), after uncovering a new mechanism linking the pathology of one with the other. It has only recently been recognized that AKI is linked to CKD and cardiovascular disease, and to date the molecular pathways that control the transition are not well-mapped. As a result, there are no therapies for preventing acute injury progressing to chronic disease.
Medshine Discovery Inc. has disclosed alkyl carboxylic acid compounds acting as soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of chronic kidney disease.
Researchers from Anhui Medical University published data from a study that aimed to assess the antifibrotic effects of the transforming growth factor-β (TGF-β) receptor type I (TGFBR1/ALK5) inhibitor Cpd-0225.
Endophilin A2 (EndoA2) is a member of the endophilin A family, and is involved in the regulation of neurological and cardiovascular diseases, as well as tumor formation. Researchers from the Second Affiliated Hospital of Guangzhou Medical University assessed the role of EndoA2 in renal fibrosis.
Viva Star Biosciences Ltd. has synthesized lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis, chronic kidney disease, diabetic nephropathy, nonalcoholic steatohepatitis (NASH), systemic scleroderma (systemic sclerosis) and idiopathic pulmonary fibrosis.
Medshine Discovery Inc. has disclosed derivatives of a six-membered heteroaromatic urea ring acting as soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of diabetic and hypertensive nephropathy.
Maze Therapeutics Inc. recently presented data from preclinical studies of a small-molecule APOL1 pore function inhibitor, MZ-301, describing the compound’s in vitro and in vivo activity. APOL1 G1 and G2 genetic variants are associated with an increased risk of progressive kidney diseases in African ancestry people. There are no APOL1-targeted therapies addressing the underlying driver of these diseases.
Gmax Biopharm LLC has received FDA clearance of its IND filing for GMA-131 injection, an ETa receptor-specific monoclonal antibody, for a phase Ib study in diabetic kidney disease (DKD).
RSS
